Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Florence Smith

Nurse Practitioner, Gerontology Livingston, NJ Nurse Practitioner

NPI 1811424419 CMS profile 11251611

200 S Orange Ave # 112, Livingston, NJ 07039

Open in the dashboard

General payments

$2,648

131 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Florence Smith of Livingston, NJ is reported in the CMS Open Payments database as having received $2,648 across 131 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 86th percentile of Nurse Practitioner, Gerontology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $665 32
2024 General $693 33
2023 General $720 32
2022 General $339 19
2021 General $231 15

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Florence Smith
  • Nurse Practitioner, Gerontology median
  • Middle half of Nurse Practitioner, Gerontology
  • National median

In program year 2025, general payments to Florence Smith were reported at $665. Among 4,139 Nurse Practitioner, Gerontology profiles paid that year, the median was $179 and the middle half received between $55 and $547.

Show as a table
Year Florence Smith Nurse Practitioner, Gerontology median Middle half National median
2019 $0 — — $163
2020 $0 — — $114
2021 $231 $133 $44–$396 $132
2022 $339 $142 $48–$452 $149
2023 $720 $158 $53–$482 $160
2024 $693 $171 $55–$533 $164
2025 $665 $179 $55–$547 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Eisai Inc. $445 20 payments
  2. Lilly USA, LLC $354 17 payments
  3. Otsuka America Pharmaceutical, Inc. $308 14 payments
  4. Pfizer Inc. $258 9 payments
  5. Ge Healthcare $232 16 payments
  6. Neurocrine Biosciences, Inc. $139 2 payments
  7. Mylan Specialty L.P. $133 7 payments
  8. Viatris Specialty LLC $108 5 payments
  9. Lundbeck LLC $102 5 payments
  10. AbbVie, Inc. $48 3 payments
  11. Other $522 33 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $2,648 131 payments
Products named General payments · program years 2021–2025
  1. Leqembi $460 21 payments
  2. REXULTI Psychiatry $276 10 payments
  3. YUPELRI $241 12 payments
  4. PAXLOVID $191 5 payments
  5. KISUNLA $138 10 payments
  6. REXULTI Psychiatry $102 5 payments
  7. COMIRNATY $69 4 payments
  8. ELIQUIS $64 4 payments
  9. PREVNAR 20 $51 3 payments
  10. AMYVID $48 3 payments
  11. Other $702 47 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 78 drugs

Part D claims

2,787

Median for Nurse Practitioner: 389

Drug cost

$142,219

Median for Nurse Practitioner: $21,885

Branded share of claims

12.2%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 71 $55,198
Jardiance Empagliflozin Brand 17 $17,379
Myrbetriq Mirabegron Brand 18 $14,354
Januvia Sitagliptin Phosphate Brand 20 $12,629
Memantine Hcl Generic 64 $3,601
Memantine Hcl Er Memantine Hcl Brand 24 $2,974
Rosuvastatin Calcium Generic 74 $1,771
Mirtazapine Generic 47 $1,640
Atorvastatin Calcium Generic 164 $1,469
Escitalopram Oxalate Generic 67 $1,401

The 10 drugs with the highest cost, of 78 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 31 billing codes

Paid by Medicare

$43,952

Of which drugs: $3,027

Medicare patients

357

Average age 85

Services billed

843

266 women, 91 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 64%
Depression 42%
Chronic kidney disease 39%
Ischemic heart disease 36%
Diabetes 33%
Osteoporosis 33%
Alzheimer's or dementia 32%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Vaccine for influenza for injection into muscle 90662 Office 18 19 $1,555
Vaccine for influenza for injection into muscle 90653 Office 14 14 $1,145
Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg J3420 Office 29 31 $29

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 8 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Leqembi
  • Eisai Inc. $312
$312 — —
REXULTI
  • Otsuka America Pharmaceutical, Inc. $50
  • Lundbeck LLC $37
$87 — —
KISUNLA
  • Lilly USA, LLC $46
$46 — —
AMYVID
  • Lilly USA, LLC $31
$31 — —
YUPELRI
  • Mylan Specialty L.P. $22
$22 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 8 in the dashboard with a free account

Records

131 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record